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Abstract
Background: PentixaFor is a promising radiopharmaceutical for positron emission
tomography in the detection of different tumor entities and other diseases. Until
now, the synthesis of [68Ga]Ga-PentixaFor was reported for the automated synthesis
module from Scintomics® only. Our aim was to evaluate the automated synthesis of
this radiopharmaceutical on a different module in order to make it available for a
broader community.
Results: The synthesis of [68Ga]Ga-PentixaFor with different amounts of PentixaFor
(50 μg, 30 μg and 20 μg) on the Modular Lab PharmTracer (MLPT) from Eckert &
Ziegler with the already established synthesis template for [68Ga]Ga-DOTATOC
yielded best results with 50 μg PentixaFor for clinical multi-dose application. All
different quality control parameters tested (e.g. sterility, stability and radiochemical
purity) were in accordance with the European Pharmacopoeia.
Conclusions: [68Ga]Ga-PentixaFor was successfully synthesized fully-automated on
the synthesis module Modular Lab PharmTracer and can be used for multi-dose
application in clinical settings.
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Background
In 2011, Demmer et al. first introduced chemokine receptor-4 (CXCR4)-binding peptidic
probes for molecular imaging (Demmer et al., 2011). PentixaFor (Synonym for CPCR4.2,
Fig. 1) is to date the most promising peptide with a high affinity to chemokine receptor-
4. PentixaFor can be used as PET imaging agent when coupled to the positron emitting
radionuclide gallium-68. Numerous clinical studies have already been performed in vivo
and the interest is steadily increasing in new applications for different tumor entities and
other diseases, e.g. inflammatory conditions (Bouter et al., 2018). Examples of clinical
applications in oncology are the detection of neuroendocrine tumors, multiple myeloma
(Pan et al., 2018), glioma, leukemia (Mayerhoefer et al., 2018) or lymphoma (Luo et al.,
2019; Haug et al., 2019). Since the precursor PentixaFor was made available until summer
2018 only for use by the synthesis module from Scintomics®, only hospitals that operated
a Scintomics® module were able to prepare [68Ga]Ga-PentixaFor. Here, we would like to
introduce the synthesis conditions of [68Ga]Ga-PentixaFor on a different synthesis
module, namely Modular Lab PharmTracer (MLPT) from Eckert & Ziegler Eurotope
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GmbH – in order to introduce [68Ga]Ga-PentixaFor to a broader community. For that
purpose, different concentrations of PentixaFor were evaluated based on quality control
parameters. Concerning the synthesis of 68Ga-tracers in general, different modules are
available on the market which have been reviewed by Boschi et al. In addition, generator
post-processing steps like fractionation, anionic-exchange and cation-exchange are
described (Boschi et al., 2013). The now proposed fully automated pre-purification of
gallium-68 on a strong cation exchange (SCX) cartridge has the advantage that gallium-68
becomes concentrated and germanium-68 as well as non-radioactive impurities (e.g.
Zn2+) are trapped on the SCX cartridge.
Results
Labeling results of different amounts of PentixaFor
The fully automated production of [68Ga]Ga-PentixaFor was conducted on the commer-
cial labeling synthesis module MLPT. Three different precursor amounts of PentixaFor
were tested for radiolabeling with 1080–2500MBq of gallium-68 (three generators from
type GalliaPharm®) - 50 μg, 30 μg and 20 μg. As shown in Table 1, the highest amount of
PentixaFor (50 μg) resulted in 94.7% radiochemical yield (RCY, n.d.c.) in the product vial,
2.6% in the waste vial and 1.7% on the C18 cartridge. By lowering the amount of Pentixa-
For to 30 μg, the RCY of the product decreased to 80.5% (n.d.c.) and the amount on the
C18 cartridge increased to 13.3% (n.d.c.). By lowering the amount of starting material to
20 μg, the efficiency became worse. Only 20.0% (n.d.c.) of radiochemical yield was found
Fig. 1 Structure of PentixaFor (molecular weight: 1221.4 g/mol)
Table 1 Activity measured on different parts of the cassette immediately after synthesis (n ≥ 3)
Product n.d.c. [%] Waste n.d.c. [%] C18 cartridge n.d.c. [%] RCY (decay corrected) [%]
50 μg 94.7 ± 0.7 2.6 ± 0.5 1.7 ± 0.5 80.9 ± 10.0
30 μg 80.5 ± 4.2 2.9 ± 1.8 13.3 ± 4.5 71.0 ± 10.6
20 μg 20.0 ± 3.2 9.3 ± 1.2 68.4 ± 2.5 18.9 ± 2.4
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in the product vial and 69.4% on the C18 cartridge. The distribution of the radioactivity in
the cassette for the productions is presented in Fig. 2.
The radioactivity found in the reactor and SCX cartridge did not change significantly
by changing the amount of starting material.
In the waste fraction, with decreasing peptide amounts from 50 to 20 μg, the radioactiv-
ity increased from 2.6% to 9.3%. Interestingly, the activity measured in the waste vial con-
sists of approximately 25% product and 75% free gallium-68 as seen in the radio-HPLC
chromatogram as well as in the radio-iTLC (Supporting Information, Fig. 1).
Quality control of [68Ga]Ga-PentixaFor
The radiochemical purity was evaluated with a standard protocol by radio-HPLC and
radio-iTLC.
With radio-HPLC, free gallium-68 would be detected at tR = 2.5 min, whereas
gallium-68 bound to PentixaFor was detected at tR = 11min. Radioactive impurities
could not be detected with this method (Fig. 3a).
With radio-iTLC, no 68Ga-colloide could be detected at Rf = 0.2 but the product at
Rf = 0.8 (Fig. 4).
The cold standard [natGa]Ga-PentixaFor shows a similar retention time of tR = 11 min
as seen in Fig. 3b.
In addition, the product solution was tested for endotoxins. For this purpose, the so-
lution was diluted with endotoxin-free-water in a ratio 1:10. For all samples, an endo-
toxin concentration below 0.5 IE/mL was detected. This is in accordance with the
European Pharmacopoeia (9.0/0125).
With regards to sterility, all products were sterile.
Fig. 2 Overview activity distribution [% of total] of different experiments n ≥ 3 (grey: 50 μg; blue: 30 μg;
light blue: 20 μg)
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The stability of [68Ga]Ga-PentixaFor in aqueous solution at room temperature was
tested up to 4 h via radio-HPLC. As seen in Fig. 5, [68Ga]Ga-PentixaFor is stable at
those conditions. No radioactive by-products or free gallium-68 could be detected dur-
ing this time period.
Fig. 3 a Radio-HPLC Chromatogram of [68Ga]Ga-PentixaFor, 50 μg. b UV-HPLC Chromatogram
of [natGa]Ga-PentixaFor
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In Table 2, product specifications of the most promising approach with 50 μg Pentix-
aFor are summarized. Acceptance criteria are based on the European Pharmacopoeia
(9.0/0125).
Discussion
For establishing the automated synthesis of [68Ga]Ga-PentixaFor on the Modular Lab
PharmTracer from Eckert & Ziegler Eurotope GmbH for the first time, three different
amounts of PentixaFor were evaluated for the production of this tracer with the same
standard synthesis template as used for [68Ga]Ga-DOTATOC on the synthesis module
MLPT. The results summarized in Table 1 and Fig. 2 demonstrate that the amount of
50 μg of PentixaFor yields the best radioactivity distribution on the cassette. The low
standard deviations for 50 μg confirm the high reproducibility of the production.
For 30 μg and 20 μg, an increasing amount of radioactivity on the C18 cartridge and a
decreasing yield of activity in the product vial was observed. Theoretically, two scenar-
ios are to our knowledge possible to explain the increased radiochemical yield on the
C18 cartridge. Either the product is trapped on the C18 cartridge or uncomplexed
68Ga-
colloide. Product could be eluted from the C18 cartridge with pure ethanol. After the
automated synthesis is completed, we tried to elute the activity. This resulted in no
change of activity measured on the C18 cartridge. As a consequence, no product is
stuck on the C18 cartridge. The most likely explanation is that 20 μg and 30 μg are too
Fig. 4 iTLC- Chromatogram of [68Ga]Ga-PentixaFor, 50 μg
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low to complex 68Ga3+ ions completely resulting in a trapping of unbound gallium-68
in the form of 68Ga3+-colloide on the C18 cartridge.
Based on the analyzation of the waste fraction by radio-HPLC and radio-iTLC,
25% of the activity found in the waste fraction was product. With respect to the
total radioactivity used in 50 μg experiments, this means a negligibly product activ-
ity loss of under 1%.
The minimum amount needed to fully complex PentixaFor under the described con-
ditions was 50 μg. In former studies in which [68Ga]Ga-PentixaFor was synthesized on
a synthesis module from Scintomics®, 40 μg and 20 μg of PentixaFor were used in a final
product volume of 15 mL and 14 mL, respectively. The amount of PentixaFor that is
safe to be used in vivo is therefore < 20 μg per patient based on those results (Lapa
et al., 2016; Wester et al., 2015). In the frame of the here described synthesis protocol,
it is important to make sure via standard operating procedures (SOPs), that the max-
imal injected amount of tracer is below 20 μg/patient. Thus, the maximum injected
volume needs to be below 3.6 mL.
With regard to the quality control parameters, we achieved an endotoxine-free, sterile
and stable solution of [68Ga]Ga-PentixaFor with a radiochemical purity > 95% over a
period of 4 h. Moreover, all tested quality control parameters were in accordance with
the European Pharmacopoeia (see Table 2). Calculating the ethanol content based on
Fig. 5 Stability of 50 μg [68Ga]Ga-Pentixafor
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the parameters chosen in the synthesis template of the MPLT software, results in an
ethanol content that cannot exceed 6.2%. Nevertheless, we recommend to either meas-
ure the ethanol content of every batch by gas chromatography before releasing it for
clinical application, or validate the ethanol content by an external laboratory if a gas
chromatography is not available onsite.
Conclusions
[68Ga]Ga-PentixaFor was successfully synthesized fully-automated on the synthesis mod-
ule MLPT for the first time. All the tested quality parameters for the radiochemical purity,
pH, endotoxins and sterility are in accordance with the European Pharmacopoeia. In
addition, the product solution is stable for at least 4 h after production, as shown by
radio-HPLC. Thus, [68Ga]Ga-PentixaFor can be easily and reliably produced on the mod-
ule MLPT for clinical application.
Methods
Materials
PentixaFor was obtained from PentixaPharm. An aqueous stock solution of 1 mg/
mL was prepared and kept at − 15 °C. All chemicals were of pure chemical grade
and solvents for high-pressure-liquid-chromatography (HPLC) were obtained as
HPLC grade. TraceSelect water (Sigma-Aldrich) was used in all experiments. The
pharmaceutical grade 68Ge/68Ga generator (GalliaPharm®, Eckert & Ziegler Radio-
pharma GmbH, Germany), Modular Lab PharmTracer (Eckert & Ziegler Eurotope
GmbH, Germany) and reagent set EZ-102 (Eckert & Ziegler Eurotope GmbH,
Germany) were used. The amount of detected metal impurities/ 68Ge breakthrough
as provided by the manufacturer was less than the defined limit in the European
Pharmacopeia monograph. Activity counting was determined using a borehole
counter (Nuklear-Medizintechnik Dresden GmbH, Germany). HPLC was performed
using the HPLC system Knauer Azura (UVD: 2.1 L; P6.1L) coupled with UV and
Table 2 Summary of the product specifications for 50 μg PentixaFor, n ≥ 3
Test Acceptance criteria [68Ga]Ga-PentixaFor
Radiochemical purity (radio-HPLC) > 95% 99.8%
Radiochemical purity (radio-iTLC) > 95% 99.7%
pH 4–8.5 5
Radioactivity concentration > 50 MBq/ mL 120–190 MBq/ mL
Radioactivity > 150 MBq 1080–1700 MBq (depending
on amount of generators used)
Volume 2–10mL 9 mL
Color Colorless Colorless
Molar radioactivity 1-60 MBq/ nmol 27-42.5 MBq/nmol
Radionuclidic purity > 99.9% 99.9 %
68Ge breakthrough < 0.001% 0.0002%
Endotoxins < 19.0 IE/mL < 0.5 IE/mL
Stability over 4 h > 90% 99.9%
EtOH content < 10% ≤ 6.2% (calculated)
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radiometric (Raytest Socket 2″8103 0370) detectors. The TLC scanner used was
MiniGita from Raytest. The test for endotoxins was performed using Nexgen PTS
(Charles River).
Preparation for labeling of PentixaFor with gallium-68
First, the commercial fully automated synthesis platform MLPT was equipped with a
disposable single-use cassette (C4-GA-PEP). The synthesis template and buffer prepara-
tions were identical to the ones used for [68Ga]Ga-DOTATOC. All synthesis reagents
were contained in the reagent set except the peptide. From the reagent set, 50 mL of
0.9% NaCl and 10 mL of EtOH/H2O (50/50) solution were connected to the cassette
on the designated spikes. After connection of the waste vial the preconditioning of the
C18 cartridge was performed automatically without user interaction. During the condi-
tioning step PentixaFor was prepared in 20 μg, 30 μg and 50 μg aliquots from the stock
solution (1 mg / mL). Meanwhile, the preparation of the acetate buffer solution was
performed according to the user manual using EZ 102. The reaction mixture contains
2.2 mL of the final buffer solution, 0.4 mL of EtOH/H2O (50/50) and an aliquot of
PentixaFor, which was loaded into the reaction vial. The required volume of eluent was
added to the eluent vial prior to synthesis.
Labeling of PentixaFor with 68GaCl3
The synthesis was performed fully-automated without any user interaction. 68Ga3+ ob-
tained from a 1.850MBq 68Ge/68Ga generator (GalliaPharm®) with TiO2 matrix, was
eluted with 0.1 N HCl. The generator eluate was pre-concentrated on a strong cation
exchange (SCX) cartridge. [68GaCl4]
− was recovered from the SCX cartridge by the
eluent (5M NaCl/HCl (0.1M)) (Schultz et al., 2013). The reaction vial containing the
reaction mixture was preheated to 50 °C, and after the 68Ga-activity was transferred to
the reaction vial, the temperature was increased to 95 °C. After 5 min at 95 °C, the reac-
tion mixture was cooled down by adding 3 mL of 0.9% NaCl. The crude reaction solu-
tion was subsequently transferred to the C18 cartridge for purification. The final
product was eluted from the C18 cartridge using a EtOH/H2O (50/50) solution and
passed through a 0.22 μm sterile filter into the sterile product vial. The resulting prod-
uct was diluted to 9 mL with 0.9% NaCl. A sample for quality control was taken.
Quality control
After synthesis, the product vial is removed from the MLPT module and further evalu-
ated for quality control determining the following parameters: total product activity,
68Ga3+-identity via half-life time, chemical purity (pH, sterility and endotoxins) and
radiochemical purity (high-pressure-liquid chromatography). The stability of the prod-
uct at room temperature was monitored by radio-HPLC for 4 h. Radio-HPLC was
performed with a standardized method. A: water + 0.1% TFA; B: acetonitrile + 0.1%
TFA, gradient: 0–25 min A: 0–100%; 25–28min A: 100–0%. The limit of detection of
the radio-HPLC is 10 kBq/ 20 μL injected volume and the recovery is approximately
80%. For iTLC, ammonium acetate/methanol (1/1) was used as mobile phase and
iTLC-SG strips as stationary phase. The sterility tests were performed as described in
the European Pharmacopoeia at the Institut für Hygiene, Charité.
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Supplementary information accompanies this paper at https://doi.org/10.1186/s41181-020-0091-2.
Additional file 1. Supporting Information, Fig. 1: iTLC chromatogram of the waste fraction
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